Prior medication of participants with T2D was predominantly metformin, then sulfonylureas, a thiazolidinedione, insulin, glucagon-like-peptide-1 receptor agonists, dipeptidyl peptidase 4 and sodium-glucose cotransporter-2 inhibitors, statins, antihypertensives, or no prior treatment. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.